TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02743546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvortuxizumab
Description: Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvortuxizumab
Description: Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
Study: NCT01462084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Level PAP
Description: Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Level PAP
Description: Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
Study: NCT03118154

Intervention type: OTHER
Intervention: Manual Physical Therapy
Description: Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
Study: NCT01556061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMAC
Description: The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMAC
Description: The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMAC
Description: The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
Study: NCT03601091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Precedex 200 MCG in 2 ML Injection
Description: Infusion therapy of the drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DORMICUM 5MG/5 ML
Description: Infusion therapy of the drug
Study: NCT04151758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid Supplementation
Description: Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Description: All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of healthy food habits
Description: All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
Study: NCT03615690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: 5 day reduced calorie diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: Regular Diet
Study: NCT01594749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant dimeglumine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT00810407

Intervention type: DRUG
Intervention: rifabutin
Description: Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.
Study: NCT02611778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study: NCT00383149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
Study: NCT01270711

Intervention type: DRUG
Intervention: Study Drug
Description: non interventional study - usage as per usual care
Study: NCT01900327

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Description: Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine neoadjuvant
Description: weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Upfront pancreato-duodenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Upfront pancreato-duodenectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine adjuvant
Description: Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
Study: NCT04363957

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Brachytherapy Consent Process
Description: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Brachytherapy Consent Process
Description: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
Study: NCT01380548

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; once/day; for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron alone
Description: Iron (3 mg); once/day; for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-dose 5-aminolevulinic acid with iron
Description: 5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium-dose 5-aminolevulinic acid with iron
Description: 5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose 5-aminolevulinic acid with iron
Description: 5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
Study: NCT00229177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506
Description: Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-2506
Description: Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
Study: NCT01900327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine adjuvant
Description: Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
Study: NCT01068119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Same-day discharge
Description: Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
Study: NCT04679792

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic posturography
Description: Balance evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic posturography
Description: Balance evaluation
Study: NCT06320730

Intervention type: OTHER
Intervention: Observational study, records of blood glucose level after reperfusion
Description: Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
Study: NCT00229177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506
Description: Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
Study: NCT01105624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin ophthalmic solution, 1%
Description: 1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visine® for Contacts®
Description: 1-2 drops QID for the treatment period (29 ± 1 day)
Study: NCT00761657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule
Study: NCT03028831

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 70g of fully digestible starch amylopectin corn starch
Description: Fully digestible amylopectin corn starch
Study: NCT00761657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT02033538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
Study: NCT02302989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Study: NCT02568449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study: NCT04213170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
Study: NCT03028831

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant starch
Description: 70g high-amylose maize starch
Study: NCT00439426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1 of each 3 week cycle
Study: NCT04527523

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: OCT is an imaging method that uses light waves to create images of the retina.
Study: NCT04217161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitor
Description: Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
Study: NCT01584674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX Biophotonic System
Description: KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
Study: NCT01444027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
Study: NCT04423601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390 tablet
Description: single oral dose of SHR6390 or co-administered with itraconazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: 200 mg itraconazole was administered in the morning.
Study: NCT01594749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Study: NCT03508323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: 20mg/qd
Study: NCT01594749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Therapy
Study: NCT03932292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin Mouth Wash
Description: According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
Study: NCT03508323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1T/qd
Study: NCT00432744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoenzymeQ10
Description: CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
Study: NCT00439426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT01080690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGD
Description: In this arm EGD will be performed before EUS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: In this arm EUS will be performed before EGD.
Study: NCT03128112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exam room with poster
Description: This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
Study: NCT03932292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supersaturated solution of calcium and phosphate ions
Description: According to medical prescription of the instruction for use under consideration (4 times a day).
Study: NCT03698695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN 201
Description: THN 201: Donepezil 5 mg and Mefloquine 10 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg/d and Mefloquine placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Donepezil placebo and Mefloquine placebo
Study: NCT02716532

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peptamen AF
Description: Each patient will receive Peptamen AF throughout the trial.
Study: NCT03853057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: body positions
Description: positive pressure ventilation at different body positions
Study: NCT02045615

Intervention type: PROCEDURE
Intervention: Proposed technique for removal of the Wichita Fusion Nail
Study: NCT03557801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mammography with Community Health Worker (individual)
Description: Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mammography with Community Health Worker (group)
Description: Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
Study: NCT03198364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety and Recovery Therapy
Description: 4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety and Recovery Therapy
Description: 4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
Study: NCT03557801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Mammography
Description: Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
Study: NCT02353806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate
Description: Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
Study: NCT03985566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre Grain
Description: Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Jasmine white rice
Description: Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
Study: NCT01486459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
Study: NCT00689351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: 7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
Study: NCT01513733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod
Description: tasquinimod 0.25 mg continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod 0.25 mg; 0.5 mg
Description: tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Description: tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
Study: NCT01766206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (Menveo)
Description: One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
Study: NCT02198313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - D2
Study: NCT02631954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorico Injection 200mg(Voriconazole)
Description: Vorico Injection 200mg(Voriconazole) to administered intravenously once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorico Injection 200mg(Voriconazole)
Description: Vorico Injection 200mg(Voriconazole) to administered intravenously once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend®(Voriconazole) IV 200mg
Description: Vfend®(Voriconazole) IV 200mg to administered intravenously once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend®(Voriconazole) IV 200mg
Description: Vfend®(Voriconazole) IV 200mg to administered intravenously once
Study: NCT03905122

Intervention type: DEVICE
Intervention: bioreactans tool
Description: It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.

Intervention type: DEVICE
Intervention: bioreactans tool
Description: It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
Study: NCT01670799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.